Market Chatter: AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition
MT Newswires Live
Aug 05
AbbVie (ABBV) has commenced a $10 billion investment-grade bond sale to help finance its pending acquisition of Apogee Therapeutics (APGE), Bloomberg reported Tuesday, citing people with direct knowledge of the matter.
The offering, which includes bonds maturing in two to 40 years, has drawn about $63 billion of peak demand, the report said, citing the people.
AbbVie didn't immediately reply to a request for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.